This is a single centre randomised controlled trial, comparing perioperative FLOT versus
adjuvant XELOX for locally advanced gastric and esophagogastric junction cancers. Patients
with operable clinical T3 or above and N1 or above gastric and esophagastric junction cancer
would be recruited. They would be randomised to perioperative FLOT versus adjuvant XELOX with
curative radical gastrectomy. Primary outcome would be 3 year Disease Free Survival. It was
calculated that 110 patients would be required to demonstrate the study hypothesis.